๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China203 Tianjin Medical University Cancer Institute and Hospital170 Tianjin Medical University Second Hospital25 Tianjin Medical University25 Tianjin Medical University General Hospital17
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Tianjin

940 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
NCT05979363Plasma Cell Leukemia
DrugAnti-BCMA CAR-T
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2023-08-14
Recruiting
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
NCT06037018Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia
DrugCC312
CytoCares Inc
Phase 1
44
Tianjin
2023-08-07
By invitation
Personalized SBRT in Early-Stage Peripheral NSCLC
NCT07167459Early-stage Peripheral Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
251
Tianjin
2023-08-04
Active, closed
S.T.O.P.ยฎ Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children
NCT05243836Myopia
nthalmic Pty Ltd
Not applicable
441
Wenzhou, Tianjin, Shanghai
2023-08-04
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
DrugBL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
130
Hefei, Beijing, Haerbin, Shenyang, Jinan, Shanghai, Chengdu, Tianjin
2023-08-02
By invitation
Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD
NCT06698211Invasive Fungal Disease, Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation
DrugPosaconazole
Institute of Hematology & Blood Diseases Hospital, China
Observational
40
Tianjin
2023-08-01
Recruiting
Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
NCT05994365Thyroid Neoplasms
DrugAnlotinib hydrochloride
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Observational
380
Beijing, Tianjin
2023-08
Active, closed
The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens
NCT05886348Myopia
HOYA Lens Thailand LTD.
Not applicable
249
Beijing, Guangzhou, Shanghai, Shengyang, Tianjin
2023-07-31
Recruiting
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
NCT06227117Breast Cancer
RemeGen Co., Ltd.
Phase 2
120
Changsha, Shanghai, Tianjin, Hangzhou
2023-07-27
Not yet open
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
NCT05940116Non-Small Cell Lung Cancer, Solid Tumor
DrugHS-20117
Hansoh BioMedical R&D Company
Phase 1
322
Tianjin
2023-07-20
Recruiting
The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
NCT05756322Relapsed or Resistant Acute Leukaemias
Lin BioScience, Inc
Phase 1/2
90
Xinxiang, Jining, Tianjin
2023-07-20
Active, closed
Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia
NCT05975996Severe Aplastic Anemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
43
Tianjin
2023-07-10
Active, closed
To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A
NCT07548411Severe Hemophilia A
DrugGS1191-0445
Gritgen Therapeutics Co., Ltd.
Phase 1/2
7
Wuhan, Tianjin
2023-07-10
Recruiting
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
NCT05884255Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
220
Shanghai, Tianjin
2023-07-06
Active, closed
CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma
NCT07809594Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
10
Tianjin
2023-07-05
Recruiting
Pre-pectoral Breast Reconstruction With or Without Mesh
NCT05888571Prepectoral Breast Reconstruction, TiLOOP Mesh
Tianjin Medical University Cancer Institute and Hospital
Not applicable
164
Tianjin
2023-07-01
Recruiting
The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
NCT05925504Lower Risk MDS Per IPSS-R
DrugLuspatercept
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
36
Tianjin
2023-07-01
Recruiting
Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
NCT05911503Cytomegalovirus Retinitis, Ganciclovir Eye Drops
Tianjin Medical University
Phase EARLY_PHASE1
15
Tianjin
2023-07-01
Active, closed
Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study
NCT07491159Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
106
Tianjin
2023-07-01
Recruiting
Pegylated Interferon ฮฑ-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
NCT05870475Polycythemia Vera
DrugsPegylated Interferon-ฮฑ 2b·Ruxolitinib
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
94
Tianjin
2023-06-30
Recruiting
A Phase Ia/Ib Open Label๏ผŒClinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
NCT05868876Advanced Malignant Tumors
Akeso
Phase 1
205
Tianjin
2023-06-29
Recruiting
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT05913804Relapsed or Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2023-06-28
Recruiting
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
NCT05830500Medullary Thyroid Cancer
DrugAnlotinib hydrochloride
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
360
Hefei, Beijing, Lanzhou, Nanning, Shijiazhuang, Tianjin, Zhengzhou, Wuhan
2023-06-19
Recruiting
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
NCT05913089Non Small Cell Lung Cancer
DrugsAnlotinib hydrochloride·Etoposide
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
58
Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin
2023-06-14
Recruiting
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
NCT05830123Osteosarcoma, Sarcoma
Hansoh BioMedical R&D Company
Phase 2
170
Beijing, Changsha, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
2023-06-08
Recruiting
Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
NCT05991336Transfusion-dependent Beta-Thalassemia, Gene Therapy
Institute of Hematology & Blood Diseases Hospital, China
Observational
100
Tianjin
2023-06-05
Active, closed
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
NCT05870917Plasma Cell Leukemia
DrugAnti-BCMA CAR-T
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2023-05-23
Active, closed
Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent ฮฒ-thalassemia.
NCT05860595Transfusion-dependent Beta-Thalassemia
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
3
Tianjin
2023-05-23
Recruiting
An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A
NCT05849740Acquired Hemophilia
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
25
Tianjin
2023-05-22
Recruiting
Gene Therapy for Diabetic Macular Edema
NCT05916391Diabetic Macular Edema
Frontera Therapeutics
Phase 1
18
Tianjin
2023-05-19
Recruiting
A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
NCT05890287HR Positive HER2 Negative Advanced Breast Cancer
DrugsTamoxifen·Anastrozole·Exemestane·Chidamide
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2023-05-16
Active, closed
A Study of a Novel Scheimpflug Device in Diagnosing Keratoconus
NCT06119321Scansys, Pentacam, Corvis ST, Keratoconus
Tianjin Eye Hospital
Observational
200
Tianjin
2023-05-04
Not yet open
Real World Study of Linperlisib for Lymphoma Treatment
NCT05863871Focus on the Lymphoma Including B/T-cell Lymphoma
Ruijin Hospital
Observational
1,000
Shanghai, Tianjin
2023-05
Recruiting
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
NCT05741359Non-hodgkin Lymphoma,B Cell
Bioray Laboratories
Phase 1
18
Wuhan, Tianjin, Hangzhou
2023-04-25
Active, closed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501Renal Cell Carcinoma
DrugsTobemstomig·Tiragolumab·Axitinib·Pembrolizumab
Hoffmann-La Roche
Phase 2
199
Beijing, Nanjing, Tianjin
2023-04-21
Active, closed
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
NCT05850286Multiple Myeloma
DrugAnti-BCMA CAR-T
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2023-04-21
Recruiting
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
NCT05738694Renal Cell Carcinoma, Neoadjuvant
ZHOU FANGJIAN
Phase 3
298
Beijing, Guangzhou, Hefei, Shanghai, Sichuan, Tianjin, Zhengzhou
2023-04-19
Recruiting
The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
NCT05630651Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
6
Tianjin
2023-04-19
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Beijing, Changchun, Shanghai, Tianjin
2023-04-17
Active, closed
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
NCT05792462NMO Spectrum Disorder
DrugBaricitinib
Tianjin Medical University General Hospital
Phase 1
11
Tianjin
2023-04-15
Recruiting
Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
NCT06141226Non-small-cell Lung Cancer
DrugsAnlotinib·Etoposide·Paclitaxel
Tianjin Medical University Cancer Institute and Hospital
Phase 2
148
Huizhou, Nanyang, Lianyungang, Weihai, Tianjin
2023-04-12
Active, closed
Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study
NCT05685550Progression Free Survival(PFS)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2023-04-12
By invitation
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
NCT05669989Plasma Cell Myeloma
DrugsIsatuximab·Carfilzomib·Cemiplimab·Pomalidomide
Sanofi
Phase 2
70
Tianjin
2023-04-05
Active, closed
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05704049Relapsed/Refractory Multiple Myeloma
Sanofi
Phase 2
118
Changsha, Guangzhou, Nanchang, Shenyang, Tianjin, Wuhan
2023-04-05
Active, closed
A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
NCT05860036Multiple Myeloma
DrugsVRD·Anti-BCMA CAR-T
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2023-04-04
Active, closed
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906Biochemically Recurrent Prostate Cancer
DrugDarolutamide
Bayer
Phase 3
985
Beijing, Wuhan, Changsha, Nanjing, Shanghai, Chengdu, Tianjin, Hangzhou
2023-04-03
Not yet open
A Study of KM501 in Patients With Solid Tumors
NCT05804864Advanced Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
96
Tianjin
2023-04
Recruiting
Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
NCT05709288Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
9
Tianjin
2023-03-23
Recruiting
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
NCT05958719Peripheral T Cell Lymphoma, Epigenetic Repression
DrugsLiposomal mitoxantrone·Chidamide·Azacitidine·Prednisone
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
37
Tianjin
2023-03-02
Recruiting
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
NCT05607498Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Phase 1
150
Changsha, Baoding, Beijing, Bengbu, Guangzhou, Harbin, Shandong, Tianjin
2023-03-01
Active, closed
Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema
NCT07106268Retinal Vein Occlusion
Tianjin Medical University Eye Hospital
Observational
100
Tianjin
2023-03-01
Active, closed
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
NCT05201066Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
DrugsDecitabine·Azacitidine·Venetoclax
Novartis Pharmaceuticals
Phase 2
33
Changchun, Tianjin
2023-02-28
Recruiting
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
NCT05701306Neuroblastoma, Solid Tumor
Ascentage Pharma Group Inc.
Phase 1/2
100
Guangzhou, Wuhan, Tianjin
2023-02-28
Recruiting
Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
NCT06254560Severe Aplastic Anemia, Platelet Transfusion Refractoriness
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2023-02-23
Recruiting
Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
NCT05751967Primary Biliary Cholangitis
DrugsFenofibrate·Ursodeoxycholic Acid
Xijing Hospital of Digestive Diseases
Phase 3
150
Lanzhou, Guangzhou, Nanjing, Shenyang, Xi'an, Chengdu, Tianjin
2023-02-22
Active, closed
Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
NCT05832684Bietti's Crystalline Dystrophy
DrugZVS101e
Chigenovo Co., Ltd
Phase 1/2
24
Beijing, Chengdu, Tianjin
2023-02-20
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Beijing, Guangzhou, Wuhan, Changsha, Jinan, Chengdu, Tianjin, Huzhou
2023-02-13
By invitation
Cognitive Impairment Characteristics and Biological Mechanisms in Untreated Severe Mental Illness
NCT07448675Patients With Severe Mental Illness
Tianjin Anding Hospital
Observational
230
Tianjin
2023-02-07
Recruiting
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
NCT05667506B-cell Acute Lymphoblastic Leukemia
DrugSingle of CNCT19
Juventas Cell Therapy Ltd.
Phase 1/2
47
Hefei, Chongqing, Guangzhou, Wuhan, Nanjing, Xuzhou, Nanchang, Tianjin
2023-02-07
Active, closed
Assessment of DOT Spectacles in Chinese Children
NCT05562622Juvenile Myopia, Myopia
SightGlass Vision, Inc.
Not applicable
195
Changsha, Chengdu, Guangzhou, Shanghai, Tianjin
2023-02-05
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
DrugsEltrombopag·Ianalumab
Novartis Pharmaceuticals
Phase 3
152
Guangzhou, Wuhan, Binzhou, Hangzhou, Beijing, Jinan, Tianjin
2023-02-02
Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
DrugsVepugratinib·Digoxin·Rosuvastatin·Enfortumab Vedotin
Eli Lilly and Company
Phase 1
677
Beijing, Guangdong, Hangzhou, Shanghai, Tianjin, Xi'an, Zhejiang
2023-01-12
Recruiting
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
NCT05640791Resectable Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
40
Tianjin
2023-01-12
Recruiting
A Study of YUTIQยฎ 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious Uveitis
NCT05592717Uveitis, YUTIQ
Tianjin Medical University
Observational
15
Tianjin
2023-01-05
By invitation
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
NCT05678933Peripheral T-cell Lymphoma Targeted Therapy
DrugsEpirubicin·Vincristine·Chidamide·Azacitidine
Tianjin Medical University Cancer Institute and Hospital
Phase 3
200
Tianjin
2023-01-01
Active, closed
Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
NCT05765032Advanced Solid Tumor
DrugSHR-A1921
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
220
Tianjin
2022-12-30
Recruiting
TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
NCT05562024B7-H3-positive Relapsed/ Refractory Neuroblastoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1
24
Jinan, Tianjin
2022-12-30
Recruiting
Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)
NCT05837806Neoadjuvant Immunotherapy
DrugsDisitamab Vedotin·Tislelizumab
Tianjin Medical University Second Hospital
Phase 2
21
Tianjin
2022-12-30
Active, closed
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
90
Guangzhou, Hangzhou, Dalian, Tianjin
2022-12-30
Active, closed
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
NCT05621499Hepatocellular Carcinoma
DrugsHAIC·Lenvatinib·Sintilimab
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2022-12-20
Active, closed
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
NCT05263583High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Cothera Bioscience, Inc
Phase 2
14
Beijing, Guangzhou, Henan, Pudong, Tianjin, Wuhan
2022-12-09
Recruiting
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
NCT05611801Hemophilia A, Hemophilia B
DrugMarstacimab
Pfizer
Phase 3
100
Beijing, Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin
2022-12-09
Recruiting
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
NCT05651672Gastrointestinal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
100
Tianjin
2022-12-02
Active, closed
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104
NCT05476887Paroxysmal Nocturnal Hemoglobinuria
Kira Pharmacenticals (US), LLC.
Phase 2
35
Beijing, Nanjing, Tianjin, Zhengzhou
2022-11-25
Active, closed
A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma
NCT05644379Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 1
30
Tianjin
2022-11-24
Recruiting
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
NCT05521802Multiple Myeloma
Shanghai AbelZeta Ltd.
Phase 1/2
92
Tianjin
2022-11-11
Recruiting
Study on the Role and Mechanism of Plasma Exosome microRNAs in Cognitive Impairment in First-episode Schizophrenia
NCT07139171Schizophrenia
Tianjin Anding Hospital
Observational
300
Tianjin
2022-11-11
Active, closed
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227Eosinophilic Esophagitis
DrugTezepelumab
AstraZeneca
Phase 3
368
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan
2022-11-10
Active, closed
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent ฮฒ-Thalassemia
NCT05577312Beta-Thalassemia
Bioray Laboratories
Phase 1/2
39
Guangzhou, Guanzhou, Shenzhen, Nanning, Changsha, Tianjin
2022-11-02
Recruiting
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
NCT05846763Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Observational
50
Tianjin
2022-11-01
Active, closed
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
NCT05403138Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
Tianjin Medical University General Hospital
Phase 2/3
135
Tianjin
2022-11-01
Recruiting
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
NCT05846750Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
59
Tianjin
2022-11-01
Recruiting
Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer
NCT05595590Head and Neck Cancer
DrugTislelizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Chengdu, Tianjin
2022-10-20
Active, closed
Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy
NCT05456698Acute Lymphocytic Leukemia
DrugInotuzumab ozogamicin
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
31
Tianjin
2022-10-18
Recruiting
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
NCT05686434NSCLC, Stage I
DrugOsimertinib
Tianjin Medical University Cancer Institute and Hospital
Phase 2
65
Tianjin
2022-10-14
Active, closed
A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer
NCT06584435High-risk Renal Cell Carcinoma
Tianjin Medical University Second Hospital
Phase 2
100
Tianjin
2022-10-10
Active, closed
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugPIT565
Novartis Pharmaceuticals
Phase 1
61
Beijing, Shanghai, Tianjin
2022-10-03
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797Multiple Myeloma
DrugsTeclistamab·Lenalidomide
European Myeloma Network B.V.
Phase 3
1,594
Beijing, Changchun, Henan, Shandong, Shanghai, Shenyang, Tangshan, Tianjin
2022-09-08
Active, closed
Toripalimab-based Neoadjuvant Therapy in LA-HNSCC
NCT05522985Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy
DrugAP
Tianjin Medical University Cancer Institute and Hospital
Phase 2
122
Tianjin
2022-09-02
Recruiting
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
NCT05446467Head and Neck Squamous Cell Carcinoma
Zhejiang Provincial People's Hospital
Phase 2
80
Qingdao, Hangzhou, Ningbo, Tianjin, Wenzhou
2022-09-01
Recruiting
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
NCT05495035Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
19
Hefei, Jinan, Tianjin, Shanghai
2022-09-01
Recruiting
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
NCT05341557Advanced Solid Tumor, Lymphoma, NSCLC, HCC
Betta Pharmaceuticals Co., Ltd.
Phase 1
110
Chaoyang, Cangzhou, Tianjin
2022-08-29
Active, closed
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT05424822Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
DrugJNJ-80948543
Janssen Research & Development, LLC
Phase 1
167
Chongqing, Guangzhou, Tianjin, Wuhan
2022-08-18
Recruiting
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
NCT06732531Bladder Cancer, Non Muscle Invasive
Zhuhai Beihai Biotech Co., Ltd
Phase 1/2
48
Beijing, Xiamen, Changsha, Shenyang, Shanghai, Tianjin
2022-08-03
Recruiting
Screening and Molecular Diagnosis-based Individualized Precision Management of Monogenic Diabetes
NCT06746610Monogenic Diabetes
Tianjin Medical University General Hospital
Not applicable
2,000
Tianjin
2022-08-01
Recruiting
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
NCT05660473Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drugs6-mercaptopurine·Pegaspargase·Daunorubicin·Methotrexate
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
100
Tianjin
2022-08-01
Recruiting
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT05067348Myasthenia Gravis, Generalized
Tang-Du Hospital
Phase 2
64
Beijing, Changsha, Xi'an, Shanghai, Chengdu, Tianjin
2022-07-21
Recruiting
A Study of FVIII Gene Therapy for Hemophilia A
NCT05454774Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
8
Tianjin
2022-07-19
Recruiting
Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
NCT05443841Esophageal Cancer
Fudan University
Observational
385
Hefei, Shijiazhuang, Zhengzhou, Nantong, Taishing, Taizhou, Xi'an, Tianjin
2022-07-18
Recruiting
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
NCT05632380Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2022-07-14
Rows per page Showing 701–800 of 940
Previous 6 7 8 9 10 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin?page=8

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 940 of those studies with a site in Tianjin.

How many clinical trials are recruiting in Tianjin?

601 of the 940 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 153 have not yet opened recruitment, 162 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.